Every time an AI alert is sent,Mingde Bio (SZ 002932, closing price: 106.19 yuan) released a performance forecast on the evening of April 13. It is expected that the net profit attributable to shareholders of listed companies in the first quarter of 2022 will be 1.35 billion yuan to 1.45 billion yuan, a year-on-year increase of 295.61% to 324.91% ; Basic earnings per share of about 12.87 yuan to about 13.83 yuan. The main reason for the change in performance is that, since January 2022, the outbreak of Omicron in many parts of the country, the number of new cases in the country has hit a new high, and the frequency of new crown nucleic acid testing has been increased for the prevention and control of the epidemic. With high-sensitivity, easy-to-operate products and high-quality customer service, the company’s market share of COVID-19 nucleic acid detection reagents continues to rise, and revenue from COVID-19 nucleic acid detection reagents and services has grown significantly. In March 2022, the comprehensive team of the State Council’s joint prevention and control mechanism for the new crown epidemic decided to add antigen testing as a supplement on the basis of nucleic acid testing. On March 15, 2022, the company newly approved the new crown antigen detection kit in China and successively won bids in many provinces across the country. The epidemic situation in Shanghai, Jilin, Shandong and other places has repeatedly increased the demand for the company’s new crown antigen detection kit, and brought to increase the operating performance of related products.
The chairman and general manager of Mingde Bio are Chen Lili, female, 48 years old, with a Ph.D.
1. In the past 30 days, a total of 1 batch of institutions has conducted research on Mingde Bio, and the total number of institutions surveyed is 27.
(Reporter Zhao Qiao)
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Do so at your own risk.
Copyright Notice
1This article is an original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, excerpting, copying or creating mirror images, etc. Violators will be held accountable.
3Copyright cooperation telephone: 021-60900099.